BRTX
BioRestorative Therapies, Inc.
Biotechnology · Healthcare · United States
1.40
close · 2026-10-30
value
5
cheaper than peers5
quality
36
stronger fundamentals36
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.59× | 92 |
| price to sales | 5.40× | 68 |
| earnings yield, 1 year ago | -82.8% | 15 |
| earnings yield, 2 years ago | -176.4% | 11 |
| earnings yield, latest year | -112.8% | 9 |
| earnings yield, 3 years ago | -260.7% | 8 |
| cash flow yield, 1 year ago | -431.1% | 3 |
| cash flow yield, 3 years ago | -328.5% | 3 |
| cash flow yield, latest year | -563.9% | 2 |
| cash flow yield, 2 years ago | -341.3% | 2 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.0% | 93 |
| revenue growth | -7.3% | 29 |
| return on equity | -241.1% | 9 |
3 of 4 measures available
Facts
| market cap | $2M |
| free cash flow | -$9.7M |
| employees | 13 |
| first trade | 2012-12-05 |
| next earnings | not reported |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.58 | -1.16 | -2.47 | -3.65 |
| free cash flow | -$10.9M | -$8.3M | -$6.6M | -$6.4M |
| net income | -$14.2M | -$9.0M | -$10.4M | -$13.2M |
| revenue | $359,700 | $401,000 | $145,800 | $119,800 |
| unusual items | $1.1M | $1.8M | $4.0M | $5.5M |